Patent · US Active

Serpin B 13 as a marker for squamous cell carcinoma of the lung

US8252542B2 · kind B2 · utility

0Cited by

0References

31Claims

0Family size

Assignee

Roche Diagnostics Operations, Inc. · US

Inventors

Markus Roessler · Germering, DE
Liliana Mantovani-Endl · Weilheim, DE
Michael Tacke · Munich, DE

Key dates

Filing date	Jul 20, 2011
Grant date	Aug 28, 2012
Priority date	—
Expiry date	Jul 20, 2031

Classification

Technology area (CPC G)Physics
CPC primaryG01N2333/8121
WIPO fieldMeasurement
WIPO sectorInstruments

Abstract

Disclosed is a method aiding in the assessment of squamous cell carcinoma (SCC). It involves the use of the protein serpin B13 as a marker of SCC. Furthermore, the disclosure relates to a method for assessing lung cancer in a tissue sample derived from a patient having non-small cell lung carcinoma (NSCLC) and for differentiating SCC from adenocarcinoma or large cell carcinoma of the lung.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.